Desloratadine expired?

When does exclusivity expire for desloratadine?

The patent for desloratadine, a popular antihistamine medication, has already expired. [1] Desloratadine was first approved by the FDA in 1998 under the brand name Clarinex [1]. The original patent for desloratadine held by Schering-Plough Corporation, now part of Merck & Co., Inc., expired in 2011. [1]

As a result, generic versions of desloratadine have been available since then. According to DrugPatentWatch.com, a reliable source for patent information, desloratadine's patent has long expired, and the medication is now available as a generic option. [2]

How does this impact patients and healthcare providers?

The expiration of desloratadine's patent has led to increased availability and affordability of the medication. Patients and healthcare providers can now access generic versions of desloratadine, which are often cheaper and more widely available. This shift to generic options has also led to increased competition in the market, driving prices down and making the medication more accessible to those in need.

However, it's essential to note that the generic versions of desloratadine are often manufactured by different companies and may have slightly different formulations or packaging. Patients and healthcare providers should ensure that any generic version used is bioequivalent to the original brand-name medication.

What does this mean for companies producing desloratadine?

The expiration of desloratadine's patent has likely affected companies that previously manufactured or marketed the brand-name version of the medication. Companies like Merck & Co., Inc. may have seen a decline in sales and revenue from the medication as generic versions became widely available. However, this also presents opportunities for companies to focus on developing new products and treatments for allergy-related conditions.

References:

[1] https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicalApplications/ucm090531.htm
[2] https://www.drugpatentwatch.com/patent/US6057106

Sources:
1. FDA.gov: FDA Approved Drugs
2. DrugPatentWatch.com: Patent Information and Analysis